Lakefront Biotherapeutics Plans 2027 Trials for Autoimmune Drug Gamgertamig with Gilead Sciences Partnership
Trendline

Lakefront Biotherapeutics Plans 2027 Trials for Autoimmune Drug Gamgertamig with Gilead Sciences Partnership

What's Happening? Lakefront Biotherapeutics is preparing to advance its autoimmune drug candidate, gamgertamig, into registrational trials as early as 2027. This move follows the acquisition of Ouro Medicines in June by Lakefront and Gilead Sciences, which added gamgertamig to Lakefront's portfolio.
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.